Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771490 | 0.87 | CYP2C9 (0.40) | LMNAL3MBTL1CYP2C9CYP3A4MAPT | |
| SCHEMBL4773852 | 0.85 | PPARG (0.41) | LMNASMN1; SMN2L3MBTL1KDM4EPPARG | |
| SCHEMBL11464003 | 0.79 | CYP2C9 (0.62) | MMEGAAMAPK1LMNASMN1; SMN2 | |
| SCHEMBL4769985 | 0.78 | CA12 (0.41) | GAALMNAL3MBTL1CYP2C9CYP3A4 | |
| SCHEMBL4771629 | 0.78 | L3MBTL1 (0.40) | LMNAL3MBTL1CYP2C9CYP3A4MAPT | |
| SCHEMBL234521 | 0.76 | GAA (0.48) | MMEGAAMAPK1LMNASMN1; SMN2 | |
| SCHEMBL31302173 | 0.76 | GAA (0.48) | MMEGAAMAPK1LMNASMN1; SMN2 | |
| SCHEMBL4771780 | 0.75 | EGFR (0.46) | CYP2C9CYP3A4MAPTKDM4ECYP1A2 | |
| SCHEMBL4773802 | 0.74 | L3MBTL1 (0.48) | LMNAL3MBTL1ESR2KMT2A | |
| SCHEMBL7367056 | 0.74 | GAA (0.46) | MMEGAAMAPK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581531-B1 | PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | claimed |
| US-7098332-B2 | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | claimed |
| EP-1581531-A1 | PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056822-A1 | PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-20040122029-A1 | Novel dihydropyridinone compounds | LIU JIN-JUN (US) | 2004-06-24 | — | — | US | claimed |
| EP-1581531-B1 | PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| EP-1581531-B1 | PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-7098332-B2 | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1581531-A1 | PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056822-A1 | PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| US-20040122029-A1 | Novel dihydropyridinone compounds | LIU JIN-JUN (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122029-A1 | Novel dihydropyridinone compounds | FGFR1, FGFR3, FGFR4 | MME 4531/4885GAA 3016/4885MAPK1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.